Neumann E, Oliveira M A, Cabral C M, Moura L N, Nicoli J R, Vieira E C, Cara D C, Podoprigora G I, Vieira L Q
Departamentos de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil.
Braz J Med Biol Res. 1998 Dec;31(12):1565-73. doi: 10.1590/s0100-879x1998001200009.
Probiotics are formulations containing live microorganisms or microbial stimulants that have some beneficial influence on the maintenance of a balanced intestinal microbiota and on the resistance to infections. The search for probiotics to be used in prevention or treatment of enteric infections, as an alternative to antibiotic therapy, has gained significant impulse in the last few years. Several studies have demonstrated the beneficial effects of lactic acid bacteria in controlling infection by intestinal pathogens and in boosting the host's nonspecific immune response. Here, we studied the use of Lactobacillus acidophilus UFV-H2b20, a lactic acid bacterium isolated from a human newborn from Viçosa, Minas Gerais, Brazil, as a probiotic. A suspension containing 10(8) cells of Lactobacillus acidophilus UFV-H2b20 was inoculated into groups of at least five conventional and germfree Swiss mice to determine its capacity to stimulate the host mononuclear phagocytic activity. We demonstrate that this strain can survive the stressing conditions of the intestinal tract in vivo. Moreover, the monoassociation of germfree mice with this strain for seven days improved the host's macrophage phagocytic capacity, as demonstrated by the clearance of a Gram-negative bacterium inoculated intravenously. Monoassociated mice showed an undetectable number of circulating E. coli, while 0.1% of the original inoculum was still present in germfree animals. Mice treated with viable or heat-killed Lactobacillus acidophilus UFV-H2b20 presented similarly improved clearance capacity when compared with germfree controls. In addition, monoassociated mice had twice the amount of Kupffer cells, which are responsible for the clearance of circulating bacteria, compared to germfree controls. These results suggest that the L. acidophilus strain used here stimulates a nonspecific immune response and is a strong candidate to be used as a probiotic.
益生菌是含有活微生物或微生物刺激物的制剂,对维持肠道微生物群平衡和抗感染能力具有一些有益影响。在过去几年中,寻找用于预防或治疗肠道感染的益生菌作为抗生素治疗的替代方法,已获得显著推动。多项研究已证明乳酸菌在控制肠道病原体感染和增强宿主非特异性免疫反应方面的有益作用。在此,我们研究了嗜酸乳杆菌UFV-H2b20(一种从巴西米纳斯吉拉斯州维索萨的一名人类新生儿中分离出的乳酸菌)作为益生菌的用途。将含有10⁸个嗜酸乳杆菌UFV-H2b20细胞的悬浮液接种到至少五只常规和无菌瑞士小鼠组中,以确定其刺激宿主单核吞噬细胞活性的能力。我们证明该菌株能够在体内肠道的应激条件下存活。此外,无菌小鼠与该菌株单联培养七天后,宿主的巨噬细胞吞噬能力得到改善,这通过静脉注射革兰氏阴性菌的清除情况得以证明。单联培养的小鼠循环中的大肠杆菌数量检测不到,而无菌动物中仍存在0.1%的原始接种物。与无菌对照组相比,用活的或热灭活的嗜酸乳杆菌UFV-H2b20处理的小鼠表现出类似的改善后的清除能力。此外,与无菌对照组相比,单联培养的小鼠中负责清除循环细菌的库普弗细胞数量增加了一倍。这些结果表明,这里使用的嗜酸乳杆菌菌株刺激了非特异性免疫反应,是用作益生菌的有力候选菌株。